Formation Bio

Formation Bio reports completing an LLM-assisted pipeline processing approximately 260,000 ClinicalTrials.gov trials into more than 6.5 million normalized study components and embeddings for reuse in trial-data analysis.

Formation Bio's February 2026 engineering report describes a launched internal intelligence platform comparing drug assets against current and future standards of care. Its LLM-guided data gathering combines human review, anomalous-value detection and source traceability. This internal asset-evaluation workflow is distinct from the existing ClinicalTrials.gov normalization pipeline; no patient or clinical success effect is demonstrated.

Formation Bio applies AI and software to drug-development and clinical-trial workflows, with real biopharma programs but narrower scale than general AI platforms.

Formation Bio's January 2026 technical article describes a seven-stage genetics-analysis pipeline combining deterministic stages with LLM parsing and synthesis, requiring human review of all LLM outputs before proceeding.

Formation Bio develops AI-enabled systems for clinical development, trial operations and pharmaceutical decision workflows.

Formation Bio develops AI-enabled systems for clinical development, trial operations and pharmaceutical decision workflows.

Formation Bio announced on June 26, 2024 that it had raised $372 million in Series D financing led by a16z, with significant participation from Sanofi.

Formation Bio combines software, clinical operations and biopharma execution capabilities in a regulated environment.

Formation Bio combines software, clinical operations and biopharma execution capabilities in a regulated environment.

Formation Bio describes a canonical ontology layer that harmonizes fragmented scientific evidence and deduplicates drug names into a shared query layer used by Atlas, Delphi, Forge, Apollo and ARK. This provides concrete data harmonization and reusable platform-engineering experience.

AI and software skills transfer to adjacent health-tech roles, while clinical-development expertise limits full cross-market portability.

AI and software skills transfer to adjacent health-tech roles, while clinical-development expertise limits full cross-market portability.